Effects of butylphthalide injection on serum IL-6, IL-1β, TNF-α and prognosis in patients with acute cerebral infarction

doi:10.11817/j.issn.1673-9248.2020.01.011

Abstract

Abstract:

Objective

To investigate the effects of butylphthalide injection on serum interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) levels and the impact of prognosis in patients with acute cerebral infarction.

Methods

80 patients with acute cerebral infarction who were hospitalized in Xuzhou Central Hospital from May 2016 to April 2018 were randomly divided into control group and treatment group, each with 40 cases. The control group was given conventional treatments such as blood pressure control, blood glucose control, lipid lowering, and anti-platelet aggregation. In addition of the conventional treatments, butylphthalide for injection was added for 14 days. The concentrations of IL-6, IL-1β, TNF-α and the National Institutes of Health Stroke Scate scores were measured before and 14 days after treatment. MOCA score were performed before and 3 months after treatment. The χ² test was used to compare the differences in total effectiveness and gender, and the independent sample t test was used to compare the differences in serum IL-6, IL-1β, TNF-α concentration, NIHSS score, and MOCA score between the groups.

Results

There were no significant differences in the concentrations of IL-6, IL-1β, TNF-α and NIHSS, MOCA scores between the two groups of patients before treatment (P＞0.05). After 14 days of treatment, the concentrations of IL-6, IL-1β, TNF-α in the treatment group decreased much more than that in the control group, and the difference was statistically significant. The NIHSS score of the treatment group was significantly lower than the control group [(6.29±1.72) pg/ml vs (7.78±1.97) pg/ml; (13.40±1.20) ng/L vs (18.12±1.30) ng/L; (1.28±0.35) pg/ml vs (1.43±0.32) pg/ml], and the difference was statistically significant. After 3 months, the MOCA score was higher than the control group [(26.38±1.60) vs (25.03±2.36)], and the difference was statistically significant.

Conclusion

Compared with the control group, the butylphthalide injection group reduced IL-6, IL-1β, TNF-α secretion in patients with acute cerebral infarction, thereby probably improving the prognosis of patients with acute cerebral infarction.

Key words: Cerebral infarction, Butylphthalide, Acute phase, Cytokines, Interleukin-6, Interleukin-1β, Tumor necrosis factor-α

Xiao Cui, Huiqin Sun. Effects of butylphthalide injection on serum IL-6, IL-1β, TNF-α and prognosis in patients with acute cerebral infarction[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2020, 14(01): 55-58.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnxgbzz.cma-cmc.com.cn/EN/10.11817/j.issn.1673-9248.2020.01.011

https://zhnxgbzz.cma-cmc.com.cn/EN/Y2020/V14/I01/55

Figures/Tables 3

References 17

1	Haegens NM, Gathier CS, Horn J, et al. Induced hypertension in preventing cerebral infarction in delayed cerebral ischemia after subarachnoid hemorrhage [J]. Stroke, 2018, 49(11): 2630-2636.
2	Perera AH, Rudarakanchana N, Monzon L, et al. Cerebral embolization, silent cerebral infarction and neurocognitive decline after thoracic endovascular aortic repair [J]. Br J Surq, 2018, 105(4): 366-378.
3	Zhang J, Wu Y, Gao Z. Correlations of C-Reactive Protein (CRP), Interleukin-6 (IL-6), and Insulin Resistance with Cerebral Infarction in Hypertensive Patients [J]. Med Sci Monit, 2019, 25: 1502-1506.
4	Chen L, Yang Q, Ding R, et al. Carotid thickness and atherosclerotic plaque stability, serum inflammation, serum MMP‑2 and MMP‑9 were associated with acute cerebral infarction [J]. Exp Ther Med, 2018, 16(6): 5253-5257.
5	Si YK, Yang Y, Xu H, et al. Effect of acupuncture on expression levels of NF-κB, IL-1β, IL-6, and TNF-α in rats with cerebral ischemia and reperfusion [J]. International Journal of Clinical and Experimental Medicine, 2018, 11(9): 9879-9885.
6	Du R, Teng JF, Wang Y, et al. Clinical study of Butylphthalide combined with Xue Shuan Tong on serum inflammatory factors and prognosis effect of patients with cerebral infarction [J]. Pak J Pharm Sci, 2015, 28(5 Suppl): 1823-1827.
7	Ying QI, Dai F, Tang W, et al. Clinical efficacy of sequential therapy for butylphthalide combined with alteplase in the treatment of acute cerebral infarction [J]. Chinese Journal of Primary Medicine and Pharmacy, 2017, 24(8): 1231-1234.
8	陈壮荣, 黄伟, 陈灵芝, 等. 奥扎雷钠联合纤溶酶对老年脑梗死患者血清炎性因子及神经递质水平的影响 [J]. 中国老年学杂志, 2019, 12(14): 3372-3374.
9	Jickling GC, Zhan X, Stamova B, et al. Ischemic transient neurological eventsidentified by immune response to cerebral ischemia [J]. Stroke, 2012, 43(4): 1006-1012.
10	Switzer JA, Sikora A, Ergul A, et al. Minocycline prevents IL-6 increase after acute ischemic stroke [J]. Transl Stroke Res, 2012, 3(3): 363-368.
11	Fahmi RM, Elsaid AF. Infarction size, interleukin-6, and their interaction are predictors of short-term stroke outcome in young egyptian adults [J]. J Stroke Cerebrovascr Dis, 2016, 25(10): 2475-2481.
12	Um JY, Moon KS, Lee KM, et al. Interleukin-1 gene cluster polymorphisms in cerebral infarction [J]. Cytokine, 2003, 23(1-2): 41-46.
13	Touzani O, Boutin H, Chuquet J, et al. Potential mechanisms of interleukin-1 involvement in cerebral ischaemia [J]. J Neuroimmunol, 1999, 100(1-2): 203-215.
14	Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke [J]. Atherosclerosis, 2010, 213(1): 311-318.
15	Boehme AK， Mcclure LA， zhang Y, et a1. Inflammatory markers and outcomes after lacunar stroke：levels of in fIammatory markers in treatment of stroke study [J]. Stroke, 2016, 47(3): 659-667.
16	Ormstad H, Aass HC, Amthor KF, et al. Serum cytokine and glucose levels as predictors of poststroke fatigue in acute ischemic stroke patients [J]. J Neurol, 2011, 258(4): 670-676.
17	Samary CS, Pelosi P, Silva PL, et al. Immunomodulation after ischemic stroke: potential mechanisms and implications for therapy [J]. Critical Care, 2016, 20(1): 391-394.

组别	例数	男/女（例）	年龄（岁，±s）	收缩压（mmHg，±s）	舒张压（mmHg，±s）	糖化血红蛋白（%，±s）	治疗前
组别	例数	男/女（例）	年龄（岁，±s）	收缩压（mmHg，±s）	舒张压（mmHg，±s）	糖化血红蛋白（%，±s）	NIHSS评分（分，±s）	MOCA评分（分，±s）
对照组	40	23/17	63.90±10.67	130.45±11.43	78.08±4.79	5.47±0.71	13.38±3.48	27.20±1.59
治疗组	40	21/19	66.55±8.53	130.95±12.97	79.25±6.53	5.70±0.78	14.07±3.73	27.18±1.10
统计值		χ²=0.202	t=0.072	t=-0.183	t=-0.918	t=-1.354	t=-0.868	t=0.099
P值		0.653	0.223	0.855	0.361	0.180	0.388	0.922

组别	例数	男/女（例）	年龄（岁，±s）	收缩压（mmHg，±s）	舒张压（mmHg，±s）	糖化血红蛋白（%，±s）	治疗前
组别	例数	男/女（例）	年龄（岁，±s）	收缩压（mmHg，±s）	舒张压（mmHg，±s）	糖化血红蛋白（%，±s）	NIHSS评分（分，±s）	MOCA评分（分，±s）
对照组	40	23/17	63.90±10.67	130.45±11.43	78.08±4.79	5.47±0.71	13.38±3.48	27.20±1.59
治疗组	40	21/19	66.55±8.53	130.95±12.97	79.25±6.53	5.70±0.78	14.07±3.73	27.18±1.10
统计值		χ²=0.202	t=0.072	t=-0.183	t=-0.918	t=-1.354	t=-0.868	t=0.099
P值		0.653	0.223	0.855	0.361	0.180	0.388	0.922

组别	例数	无效	有效	显效	总有效
对照组	40	10（25.0）	14（35.0）	16（40.0）	30（75.0）
治疗组	40	3（7.5）	10（25.0）	27（67.5）	37（92.5）

组别	例数	无效	有效	显效	总有效
对照组	40	10（25.0）	14（35.0）	16（40.0）	30（75.0）
治疗组	40	3（7.5）	10（25.0）	27（67.5）	37（92.5）

组别	例数	IL-6（pg/ml）		IL-1β（ng/L）		TNF-α（pg/ml）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	40	10.40±2.82	7.78±1.97	25.06±2.86	18.12±1.30	1.90±0.46	1.43±0.32
治疗组	40	11.11±3.05	6.29±1.72	25.79±2.74	13.40±1.20	1.95±0.62	1.28±0.35
t值		-1.089	3.586	-1.168	16.875	-0.405	2.002
P值		0.279	0.001	0.246	＜0.001	0.686	0.049

Please choose a citation manager

Content to export